Epitope Conservation of AZD5148, a Broadly Neutralizing Anti-Toxin B Monoclonal Antibody, Among Diverse and Global Contemporary Clostridioides difficile Isolates - Takeaways - MDSpire

Epitope Conservation of AZD5148, a Broadly Neutralizing Anti-Toxin B Monoclonal Antibody, Among Diverse and Global Contemporary Clostridioides difficile Isolates

  • By

  • Kelly Ann Mahool

  • Emily Nguyen

  • Victoria Godfrey

  • Ann Marie Stanley

  • Tyler Brady

  • Adam Gamson

  • Kim Rosenthal

  • Justin Green

  • Ondrej Podlaha

  • Bret R Sellman

  • Christine Tkaczyk

  • Vancheswaran Gopalakrishnan

  • August 14, 2025

  • 0 min

Share

  • 1

    AZD5148 is a human monoclonal antibody that neutralizes Clostridioides difficile toxin B, targeting a conserved epitope on the glucosyltransferase domain.

  • 2

    The binding epitope for AZD5148 shows a high conservation frequency of 99.58% across diverse global C. difficile strains, surpassing bezlotoxumab's 82.47%.

  • 3

    In vitro studies demonstrated that AZD5148 effectively neutralizes cytotoxicity from eight recently circulating C. difficile ribotypes.

  • 4

    Analysis of 9134 global C. difficile genomes confirmed that key residues for AZD5148 neutralization are conserved, indicating resilience to genotypic variations.

  • 5

    This study highlights the potential of AZD5148 as a promising therapeutic option for preventing C. difficile infection recurrence.

Original Source(s)

Epitope Conservation of AZD5148, a Broadly Neutralizing Anti-Toxin B Monoclonal Antibody, Among Diverse and Global Contemporary Clostridioides difficile Isolates

  • by Kelly Ann Mahool, Emily Nguyen, Victoria Godfrey, Ann Marie Stanley, Tyler Brady, Adam Gamson, Kim Rosenthal, Justin Green, Ondrej Podlaha, Bret R Sellman, Christine Tkaczyk, Vancheswaran Gopalakrishnan

  • August 14, 2025

Related Content

Match Day results show impact of federal immigration policy

Framework Targets Hospital-Onset UTIs

The expert panel outlines surveillance, device management, and diagnostic stewardship strategies to address both catheter-associated and non–catheter-associated infections.

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.